Skip to main content
Premium Trial:

Request an Annual Quote

Dublin City University, Sigma-Aldrich, Alnylam, Inex, Protiva

Premium
Dublin City University Joins Sigma-Aldrich’s RNAi Partnership Program
 
Sigma-Aldrich said this week that Dublin City University has joined the company’s RNAi Partnership Program.
 
The program was established earlier this year as part of Sigma-Aldrich’s bid to strengthen ties between the company and academic users of its RNAi and other functional genomics products, as well as boost the company's visibility in the RNAi space (see RNAi News, 4/27/2006).
 
Participants in the program will get early access to new Sigma-Aldrich technologies, and will have a dedicated support team to assist with products from the company's functional genomics product portfolio.
 
Other members of the RNAi Partnership Program include Rutgers University; the University of Medicine and Dentistry, New Jersey; the Wistar Institute; Tufts University; Washington University of Saint Louis; and Moore's Cancer Center, UCSD.

 
Alnylam Initiates Experimental Infection Study of RSV Drug
 
Alnylam Pharmaceuticals said this week that it has initiated a phase I experimental infection study of its respiratory syncytial virus drug ALN-RSV01.
 
The trial’s protocol calls for 40 healthy adults to receive gradually increasing levels of virus in order to determine the optimal infectious inoculum, Alnylam said. “Following determination of the optimal level of the RSV inoculum, Alnylam expects the next stage of this program will be performed with a separate clinical protocol using ALN-RSV01 in order to investigate the drug's anti-viral properties,” the drug developer added.
 
Alnylam said that a phase II trial of ALN-RSV01 in naturally infected patients is expected to begin in the first half of 2007.
 

 
Canadian Court OKs Inex’s Planned Spin Out, Rules Protiva’s US Suit Can Proceed
 
Inex Pharmaceuticals this week said that the British Columbia Supreme Court has ruled the company can proceed with its planned spin out of its assets into a newly created firm, Tekmira Pharmaceuticals.
 
The spin-out plan calls for the transfer of all Inex’s assets to Tekmira, including its drug-delivery collaboration with Alnylam Pharmaceuticals (see RNAi News, 3/30/2006). One-time Inex subsidiary Protiva Biotherapeutics had challenged the spin out as part of an ongoing legal dispute over the drug-delivery technology that includes Alnylam and Sirna Therapeutics (see RNAi News, 11/9/2006).
 
According to Protiva, it has until Dec. 27 to appeal the court’s ruling.
 
Protiva also said this week that the court dismissed Inex’s request to block Protiva from moving ahead with its lawsuit against Inex in San Francisco (see RNAi News, 9/14/2006).

The Scan

Boosters Chasing Variants

The New York Times reports that an FDA advisory panel is to weigh updated booster vaccines for COVID-19.

Not Yet

The World Health Organization says monkeypox is not yet a global emergency, the Washington Post reports.

More Proposed for Federal Research

Science reports that US House of Representatives panels are seeking to increase federal research funding.

PLOS Papers on Breast Cancer Metastasis, Left-Sided Cardiac Defects, SARS-CoV-2 Monitoring

In PLOS this week: link between breast cancer metastasis and CLIC4, sequencing analysis of left-sided cardiac defects, and more.